BIS Announces Comprehensive Assessment of Active Pharmaceutical Ingredient Industrial Base

The agency, along with the HHS's Office of Industrial Base Management and Supply Chain, will survey API manufacturers, distributors, suppliers, and customers.

The U.S. Department of Commerce’s Bureau of Industry and Security (BIS) announced that “the U.S. government is conducting a comprehensive assessment of the U.S. Active Pharmaceutical Ingredient (API) industrial base to gain an understanding of the supply chain network that underpins U.S. pharmaceutical manufacturing capabilities.” BIS's website has the release.

With this information, the federal government will be able to “more accurately plan and develop funding strategies to help ensure the availability and security of the API supply chain and to raise awareness of current limited domestic manufacturing capabilities, among other potential issues.”

BIS will survey “hundreds of U.S. API manufacturers, distributors, suppliers, and customers” in support of this goal. The effort will “identify interdependencies between respondents, suppliers, customers, and U.S. government agencies while also benchmarking performance across multiple tiers of the API industry.”

The assessment was requested by “HHS’s Administration for Strategic Preparedness and Response (ASPR) to support its mission to build a diverse, agile public health supply chain and sustain long-term U.S. manufacturing capabilities.”

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates